Charu Aggarwal

University of Pennsylvania

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (10)

Stephen Liu

Associate Professor

Georgetown University School of Medicine

UNITED STATES

View details

Joshua Reuss

Assistant Professor of Medicine

UNITED STATES

View details

Alberto J. Montero

UNITED STATES

View details

Christian Rolfo

Prof. Dr. Head of Phase I- Early Clinical Trials Unit, Director of Clinical Trials Management Program.

Universitair Ziekenhuis Antwerpen

BELGIUM

View details

Roger Blumenthal

Johns Hopkins University School of Medicine

UNITED STATES

View details

Mercedes Porosnicu

Wake Forest School of Medicine

UNITED STATES

View details

Tanguy Seiwert

Johns Hopkins University

UNITED STATES

View details

Missak Haigentz

Professor of Medicine and Chief, Thoracic and Head & Neck Medical Oncology

Rutgers Cancer Institute of New Jersey

UNITED STATES

View details

Woong-Yang Park

Professor

Sungkyunkwan University

SOUTH KOREA

View details

Harikrishnan Hyma Kunhiraman

Augusta University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Charu Aggarwal

Research Interests

Explore related searches

Contact this professor

Articles (19)

A novel machine learning-based cancer-specific cardiovascular disease risk score among patients with breast, colorectal, or lung cancer

Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status—A Real-World Analysis in Patients With Advanced NSCLC

Toward Response-Adaptive Therapy in Locally Advanced NSCLC: Integrating ctDNA and Radiomics for Risk Stratification

Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions

Management of Patients With EGFR Exon 20–Mutant Advanced Non–Small Cell Lung Cancer

Precision Oncology: A Global Perspective on Implementation and Policy Development

Differential Survival Among Patients With Cancer by COVID-19 Vaccination Status: An Analysis of the ASCO COVID-19 Registry

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Zipalertinib in EGFR Exon 20–Mutant Non–Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting

Targeting<i>KRAS</i>-Mutated NSCLC: Novel TKIs and Beyond

Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond

MEDI0457 Plus Durvalumab in HPV-associated HNSCC—Response

Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis

Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?

Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry

Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice

Adjuvant Osimertinib: A New Standard of Care

Collaborators (10)

Stephen Liu

Joshua Reuss

Alberto J. Montero

Christian Rolfo

Roger Blumenthal

Mercedes Porosnicu

Tanguy Seiwert

Missak Haigentz

Woong-Yang Park

Harikrishnan Hyma Kunhiraman

Make your next move.